TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 22504052

Group type: EXPERIMENTAL
Intervention: Sun protection advice delivered orally during a doctor's consultation (Group 2)
Number of subjects: 213

Group type: COMPARATOR
Intervention: Sun protection advice delivered in letter-form (Group 1)
Number of subjects: 213
Study: 19943985

Group type: EXPERIMENTAL
Intervention: High meal frequency (3 meals + 3 snacks/d)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Low meal frequency (3 meals/d)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Both groups (high MF and low MF)
Number of subjects: 16
Study: 18598834

Group type: EXPERIMENTAL
Intervention: Thermal welding tonsillectomy (TWT)
Number of subjects: 143

Group type: COMPARATOR
Intervention: Ligasure tonsillectomy (LT)
Number of subjects: 143
Study: 15763437

Group type: EXPERIMENTAL
Intervention: Fish oil (8 g/day for 6 weeks)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 12188054

Group type: EXPERIMENTAL
Intervention: Personal self-management coach
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Social support intervention
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Personal self-management coach and support intervention
Number of subjects: 160

Group type: COMPARATOR
Intervention: Diabetes information only
Number of subjects: 160
Study: 10483898

Group type: EXPERIMENTAL
Intervention: Ala‐Gln (Dipeptiven, 0.50 g/kg per day)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control group (isonitrogenous and isocaloric PN)
Number of subjects: 120
Study: 8743406

Group type: EXPERIMENTAL
Intervention: 250 mg naproxen
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: 500 mg naproxen
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Higher doses of naproxen
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Lower doses of naproxen
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Naproxen (general)
Number of subjects: 28
Study: 1686440

Group type: EXPERIMENTAL
Intervention: NAAXIA (Na+ salt of N-acetyl-aspartylglutamic acid)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Previous formula (Mg++ salt of N-acetyl-aspartylglutamic acid)
Number of subjects: 0
Study: 6435085

Group type: EXPERIMENTAL
Intervention: Cromolyn sodium
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Sustained-release theophylline (Theo-Dur)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Placebo for cromolyn
Number of subjects: 46

Group type: COMPARATOR
Intervention: Placebo for theophylline
Number of subjects: 46
Study: 30136743

Group type: COMPARATOR
Intervention: Doll Therapy (DT)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Gesture-Verbal Treatment (GVT)
Number of subjects: 30
Study: 30413519

Group type: EXPERIMENTAL
Intervention: Smartphone-based problem-solving therapy (PST) and behavioural activation (BA) apps (Kaiketsu-App and Genki-App) plus treatment as usual (TAU)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Waitlist control with treatment as usual (TAU) alone
Number of subjects: 0
Study: 26856215

Group type: EXPERIMENTAL
Intervention: Normal-low potassium target (nLP group, 4.0 mmol/L)
Number of subjects: 910

Group type: COMPARATOR
Intervention: Normal-high potassium target (nHP group, 4.5 mmol/L)
Number of subjects: 910
Study: 25417401

Group type: EXPERIMENTAL
Intervention: Xinfeng capsule (XFC) treatment group
Number of subjects: 300

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 300
Study: 23176374

Group type: EXPERIMENTAL
Intervention: Myofascial techniques (suboccipital muscle release, fourth intracranial ventricle compression, deep cervical fascia release)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Control group (resting position)
Number of subjects: 39
Study: 21958494

Group type: EXPERIMENTAL
Intervention: Meropenem (20 mg/kg q12h or q8h depending on age)
Number of subjects: 550

Group type: COMPARATOR
Intervention: Standard of care (ampicillin + gentamicin or cefotaxime + gentamicin)
Number of subjects: 550
Study: 18431478

Group type: EXPERIMENTAL
Intervention: Oral amoxycillin (31-54 mg/Kg/day, in three divided doses for three days)
Number of subjects: 1671

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1671
Study: 16645974

Group type: EXPERIMENTAL
Intervention: Computer-based method for measuring joint space width
Number of subjects: 129

Group type: COMPARATOR
Intervention: Sharp joint space narrowing (JSN) subscale
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: Signal-to-noise ratio for computer-based method
Number of subjects: 129
Study: 16191242

Group type: EXPERIMENTAL
Intervention: Memantine at a standard daily dose of 10 mg b.i.d.
Number of subjects: 900

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 900
Study: 10798610

Group type: EXPERIMENTAL
Intervention: n-3 polyunsaturated fatty acids (n-3 PUFAs) - fish oil extract (EPA 3.2 g, DHA 2.4 g)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Sunflower oil (control)
Number of subjects: 18
Study: 8689472

Group type: EXPERIMENTAL
Intervention: Memory and reattribution training
Number of subjects: 442

Group type: EXPERIMENTAL
Intervention: Physical training
Number of subjects: 442

Group type: EXPERIMENTAL
Intervention: Psychoanalytical group therapy
Number of subjects: 442
Study: 1686811

Group type: EXPERIMENTAL
Intervention: D,L-fenfluramine (60 mg, oral)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 6414339

Group type: EXPERIMENTAL
Intervention: Fentanyl 10 micrograms/kg
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Fentanyl 25 micrograms/kg
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 24
Study: 31668850

Group type: EXPERIMENTAL
Intervention: Palbociclib plus endocrine therapy (oral exemestane 25 mg per day for 28 days, oral palbociclib 125 mg per day for 21 days every 4 weeks, plus leuprolide 3·75 mg subcutaneously every 4 weeks)
Number of subjects: 184

Group type: COMPARATOR
Intervention: Capecitabine (oral capecitabine 1250 mg/m2 twice daily for 2 weeks every 3 weeks)
Number of subjects: 184
Study: 30373597

Group type: EXPERIMENTAL
Intervention: Intervention youth
Number of subjects: 534

Group type: EXPERIMENTAL
Intervention: Older intervention youth
Number of subjects: 534

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 534
Study: 27634549

Group type: EXPERIMENTAL
Intervention: Cancer@Work intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Care as usual
Number of subjects: 0
Study: 24598375

Group type: EXPERIMENTAL
Intervention: Occupational physician condition (screening, feedback, and referral to the occupational physician)
Number of subjects: 617

Group type: EXPERIMENTAL
Intervention: e-mental health condition (screening, feedback, and referral to e-mental health)
Number of subjects: 617

Group type: COMPARATOR
Intervention: Control condition (online screening without feedback)
Number of subjects: 617

Group type: COMPARATOR
Intervention: Occupational physician condition vs Control condition
Number of subjects: 617

Group type: COMPARATOR
Intervention: e-mental health condition vs Control condition
Number of subjects: 617
Study: 22322821

Group type: EXPERIMENTAL
Intervention: Biofeedback system using hemodiafiltration with online regeneration of ultrafiltrate (HFR) in isonatric mode
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard hemodialysis (implied control)
Number of subjects: 0
Study: 20180717

Group type: EXPERIMENTAL
Intervention: Artelon CMC spacer (test, n = 72)
Number of subjects: 109

Group type: COMPARATOR
Intervention: Tendon interposition arthroplasty (control, n = 37)
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 109
Study: 17616331

Group type: EXPERIMENTAL
Intervention: HCV treatment (n=24)
Number of subjects: 223

Group type: COMPARATOR
Intervention: HIV treatment only (n=115)
Number of subjects: 223
Study: 15832066

Group type: EXPERIMENTAL
Intervention: Self-exposure cognitive behaviour therapy (CBT) via FearFighter (FF)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Minimal CBT without exposure via Managing Anxiety (MA)
Number of subjects: 68
Study: 12504203

Group type: EXPERIMENTAL
Intervention: Children with congenital hemiparesis (left hemisphere lesion)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Children with congenital hemiparesis (right hemisphere lesion)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Children with congenital hemiparesis (ipsilateral to brain lesion handedness)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Children with congenital hemiparesis (contralateral to lesion handedness)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 56
Study: 9817161

Group type: EXPERIMENTAL
Intervention: Anti-GM-CSF
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Mixture of antibodies to IL-3, IL-5 and GM-CSF
Number of subjects: 28

Group type: COMPARATOR
Intervention: Eosinophil survival-enhancing activity (ESEA)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Correlation with eosinophils and CD25(+)CD4 lymphocytes
Number of subjects: 28
Study: 8699035

Group type: EXPERIMENTAL
Intervention: Tear glucose measurement using Dextrostix (glucose oxidase method)
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Tear glucose measurement
Number of subjects: 94
Study: 2693162

Group type: EXPERIMENTAL
Intervention: Ranitidine 300 and 600 mg daily
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 356900

Group type: EXPERIMENTAL
Intervention: EMG BFT
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Meditation
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: PMR
Number of subjects: 54

Group type: COMPARATOR
Intervention: Control
Number of subjects: 54

Group type: COMPARATOR
Intervention: Placebo Control
Number of subjects: 54
Study: 31282402

Group type: EXPERIMENTAL
Intervention: Tai Chi (TC)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Taekkyon
Number of subjects: 46
Study: 29725853

Group type: EXPERIMENTAL
Intervention: Duo (D) implant
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Integra (IN) implant
Number of subjects: 23

Group type: COMPARATOR
Intervention: Standard geometry, Duo (D), Compact (C), Infra (IF) implants
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Healing time
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: ISQ
Number of subjects: 23
Study: 27385541

Group type: EXPERIMENTAL
Intervention: Aerobic plus resistance training (N=97)
Number of subjects: 148

Group type: COMPARATOR
Intervention: Aerobic training (N=51)
Number of subjects: 148
Study: 25454337

Group type: EXPERIMENTAL
Intervention: Active tDCS (2 mA, 10 sessions over 1 week)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Active tDCS
Number of subjects: 24
Study: 23519639

Group type: EXPERIMENTAL
Intervention: Diagnosis of prostate cancer
Number of subjects: 678

Group type: COMPARATOR
Intervention: Active monitoring after diagnosis
Number of subjects: 678
Study: 21802124

Group type: EXPERIMENTAL
Intervention: Tamsulosin (0.4 mg daily for ≤30 days)
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: Nifedipine (20 mg retard daily for ≤30 days)
Number of subjects: 136

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: Tamsulosin (for stones 10-20 mm)
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: Nifedipine (for stones 10-20 mm)
Number of subjects: 136

Group type: COMPARATOR
Intervention: Placebo (for stones 10-20 mm)
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: Tamsulosin
Number of subjects: 136
Study: 19406908

Group type: EXPERIMENTAL
Intervention: Clodronate 0.5 mg one IA injection/week for 4 weeks
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Clodronate 1 mg one IA injection/week for 4 weeks
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Clodronate 2 mg one IA injection/week for 4 weeks
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Clodronate 1 mg two IA injections/week for 2 weeks
Number of subjects: 150

Group type: COMPARATOR
Intervention: Hyaluronic Acid (HA) 20 mg one IA injection/week for 4 weeks
Number of subjects: 150
Study: 16772320

Group type: EXPERIMENTAL
Intervention: Hydrocortisone (HC) 1.5 microg x kg(‐1) x min(‐1)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Saline
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Hydrocortisone (HC)
Number of subjects: 16
Study: 12749718

Group type: EXPERIMENTAL
Intervention: Continued smoking after index diagnosis
Number of subjects: 1181

Group type: EXPERIMENTAL
Intervention: Continued alcohol consumption post-diagnosis
Number of subjects: 1181

Group type: EXPERIMENTAL
Intervention: Older age at diagnosis
Number of subjects: 1181

Group type: EXPERIMENTAL
Intervention: Stage II diagnosis
Number of subjects: 1181

Group type: EXPERIMENTAL
Intervention: Index diagnosis of pharyngeal cancer
Number of subjects: 1181
Study: 10770979

Group type: EXPERIMENTAL
Intervention: Low-fat, high-fiber diet (20% of total calories from fat, 18g of dietary fiber per 1000 kcal, 3.5 servings of fruits and vegetables per 1000 kcal)
Number of subjects: 2079

Group type: COMPARATOR
Intervention: Standard brochure on healthy eating (control group)
Number of subjects: 2079

Group type: EXPERIMENTAL
Intervention: Low-fat, high-fiber diet
Number of subjects: 2079
Study: 9594153

Group type: EXPERIMENTAL
Intervention: Repeated Transient Dearterialization (RTD)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Hepatic Artery Ligation (HAL)
Number of subjects: 40
Study: 1357998

Group type: EXPERIMENTAL
Intervention: LH‐RH plus somatostatin
Number of subjects: 163

Group type: EXPERIMENTAL
Intervention: LH‐RH
Number of subjects: 163

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 163

Group type: EXPERIMENTAL
Intervention: Somatostatin
Number of subjects: 163

Group type: EXPERIMENTAL
Intervention: Hormone therapy (combined regimens)
Number of subjects: 163
Study: 3993552

Group type: EXPERIMENTAL
Intervention: Propranolol (160 mg/day)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Atenolol (100 mg)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study: 30110008

Group type: EXPERIMENTAL
Intervention: Cold tumescence anesthesia solution (4 ℃)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Room temperature tumescence anesthesia solution (24 ℃)
Number of subjects: 51
Study: 27707724

Group type: EXPERIMENTAL
Intervention: Hyperinsulinemic-normoglycemic clamp with AA supplementation
Number of subjects: 20

Group type: COMPARATOR
Intervention: Hyperinsulinemic-normoglycemic clamp without AA supplementation
Number of subjects: 20
Study: 25079064

Group type: COMPARATOR
Intervention: Ranibizumab monotherapy
Number of subjects: 255

Group type: EXPERIMENTAL
Intervention: Combination therapy (verteporfin PDT and ranibizumab)
Number of subjects: 255

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 255
Study: 22824071

Group type: EXPERIMENTAL
Intervention: Hand curettes
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Ultrasonic scalers
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Er:YAG laser
Number of subjects: 30
Study: 20050938

Group type: EXPERIMENTAL
Intervention: Sildenafil (50-100 mg)
Number of subjects: 105

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 105
Study: 18322360

Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (MMF)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Azathioprine (Aza)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Healthy controls (HCs)
Number of subjects: 40
Study: 15522858

Group type: EXPERIMENTAL
Intervention: Intake of fried foods away from home (highest quintile)
Number of subjects: 37547

Group type: COMPARATOR
Intervention: Total fat intake
Number of subjects: 37547

Group type: COMPARATOR
Intervention: Different types of fat and major fatty acids intake
Number of subjects: 37547
Study: 11583868

Group type: EXPERIMENTAL
Intervention: Detectable troponin T (tnT) levels
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High levels of troponin T (tnT)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Noninvasive arm of the study
Number of subjects: 0
Study: 9267791

Group type: EXPERIMENTAL
Intervention: Total Androgen Blockade (TAB) by bilateral orchiectomy and flutamide 250 mg t.i.d.
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: Combined Total Androgen Blockade plus weekly epirubicin 25 mg/m2 i.v. for 18 weeks (E-TAB)
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: Total Androgen Blockade (TAB)
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: Combined Total Androgen Blockade plus weekly epirubicin (E-TAB)
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: E-TAB in patients with > 5 sites of bone metastasis (D2max)
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: TAB in patients with > 5 sites of bone metastasis (D2max)
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: E-TAB
Number of subjects: 145

Group type: COMPARATOR
Intervention: TAB
Number of subjects: 145
Study: 7506154

Group type: EXPERIMENTAL
Intervention: Nimesulide 100mg 3 times daily
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 3101530

Group type: EXPERIMENTAL
Intervention: High branched-chain amino acid formula (11 patients)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Low branched-chain amino acid formula (9 patients)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control group (8 patients, 5% dextrose in water solution)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Jejunostomy groups (High and Low branched-chain amino acid)
Number of subjects: 28
Study: 29568790

Group type: EXPERIMENTAL
Intervention: Psychiatric‐psychosomatic consultation with recommendations provided to GPs
Number of subjects: 307

Group type: COMPARATOR
Intervention: Standard care without psychiatric‐psychosomatic consultation
Number of subjects: 307
Study: 27852589

Group type: EXPERIMENTAL
Intervention: Inclacumab 20 mg/kg
Number of subjects: 544

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 544
Study: 24840109

Group type: COMPARATOR
Intervention: Clomiphene citrate (CC) 100 mg daily for 5 days starting on day 5 of menses (Group 1)
Number of subjects: 252

Group type: EXPERIMENTAL
Intervention: Clomiphene citrate (CC) 100 mg daily for 5 days starting the next day after finishing medroxyprogesterone acetate (MPA) (Group 2)
Number of subjects: 252

Group type: EXPERIMENTAL
Intervention: Clomiphene citrate (CC) (Group 2)
Number of subjects: 252
Study: 22872647

Group type: EXPERIMENTAL
Intervention: Entecavir 1.0 mg/day
Number of subjects: 72

Group type: COMPARATOR
Intervention: Lamivudine 100 mg/day
Number of subjects: 72
Study: 20309947

Group type: EXPERIMENTAL
Intervention: Modified Clinical Signs and Symptoms Checklist
Number of subjects: 0
Study: 18689159

Group type: EXPERIMENTAL
Intervention: Hormone Replacement Therapy (HRT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (no HRT)
Number of subjects: 0
Study: 17148514

Group type: EXPERIMENTAL
Intervention: Thermoplastic resting splint during weeks 2-3 and weeks 4-7
Number of subjects: 14

Group type: COMPARATOR
Intervention: No splint during week 2, then wore a splint during week 3, and wore a splint through weeks 4-7
Number of subjects: 14
Study: 12825872

Group type: EXPERIMENTAL
Intervention: Flexible Sigmoidoscopy (FS)
Number of subjects: 20780

Group type: COMPARATOR
Intervention: Combination of FS and FOBT
Number of subjects: 20780
Study: 10713235

Group type: EXPERIMENTAL
Intervention: BSS Plus
Number of subjects: 80

Group type: COMPARATOR
Intervention: Ringer's solution
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Room-temperature BSS Plus
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Refrigerated fortified BSS Plus
Number of subjects: 80

Group type: COMPARATOR
Intervention: Modified Ringer's solution
Number of subjects: 80
Study: 8806333

Group type: EXPERIMENTAL
Intervention: Primary Percutaneous Transluminal Coronary Angioplasty (PTCA)
Number of subjects: 395

Group type: COMPARATOR
Intervention: Tissue Plasminogen Activator (tPA)
Number of subjects: 395
Study: 1353507

Group type: EXPERIMENTAL
Intervention: nebivolol 5 mg once a day (n = 26)
Number of subjects: 51

Group type: COMPARATOR
Intervention: nifedipine sustained-release 20 mg bid (n = 25)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: nebivolol
Number of subjects: 51

Group type: COMPARATOR
Intervention: nifedipine
Number of subjects: 51
Study: 6426618

Group type: EXPERIMENTAL
Intervention: Verbal and written antismoking advice from the general practitioner
Number of subjects: 2110

Group type: EXPERIMENTAL
Intervention: Advice plus demonstration of exhaled carbon monoxide
Number of subjects: 2110

Group type: EXPERIMENTAL
Intervention: Advice plus offer of further help from a health visitor
Number of subjects: 2110

Group type: COMPARATOR
Intervention: Control (non-intervention) group
Number of subjects: 2110
Study: 30894212

Group type: EXPERIMENTAL
Intervention: Epacadostat (25, 50, 100, or 300 mg BID; 75 mg daily; or 50 mg BID intermittent) plus ipilimumab 3 mg/kg every 3 weeks
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Epacadostat (various doses) plus ipilimumab
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Epacadostat (≥25 mg BID) plus ipilimumab
Number of subjects: 50
Study: 29975061

Group type: EXPERIMENTAL
Intervention: Low-fat milk
Number of subjects: 19

Group type: COMPARATOR
Intervention: Rice milk
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Low-fat milk and rice milk
Number of subjects: 19
Study: 27757013

Group type: EXPERIMENTAL
Intervention: Frovatriptan
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Frovatriptan + Dexketoprofen
Number of subjects: 0
Study: 24462492

Group type: EXPERIMENTAL
Intervention: Scented condition (pear odour)
Number of subjects: 115

Group type: COMPARATOR
Intervention: Control condition (non-odorised waiting room)
Number of subjects: 115
Study: 23114185

Group type: EXPERIMENTAL
Intervention: Loxostylis alata extract at doses of 100 mg/kg and 200 mg/kg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ketoconazole at a dose of 60 mg/kg
Number of subjects: 0
Study: 19157710

Group type: EXPERIMENTAL
Intervention: Infants with a maternal family history of hypertension
Number of subjects: 80

Group type: COMPARATOR
Intervention: Infants without a maternal family history of hypertension
Number of subjects: 80
Study: 17065169

Group type: EXPERIMENTAL
Intervention: i.v. remifentanil 1 microg kg(‐1)
Number of subjects: 70

Group type: COMPARATOR
Intervention: i.v. saline 5 ml (control)
Number of subjects: 70
Study: 15547166

Group type: EXPERIMENTAL
Intervention: Prone position placement (n = 413)
Number of subjects: 791

Group type: COMPARATOR
Intervention: Supine position placement (n = 378)
Number of subjects: 791
Study: 11868855

Group type: EXPERIMENTAL
Intervention: 1 gm/day hydroalcoholic extract of fenugreek seeds
Number of subjects: 25

Group type: COMPARATOR
Intervention: Usual care (dietary control, exercise) and placebo capsules
Number of subjects: 25